Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest added to existing positions in Meta, Airbnb, and Beam Therapeutics on Monday. Meta rose 11% in its largest one-day gain in over a year as its two-week-old Muse agentic-AI app reached No. 1 in the App Store Productivity category; Wells Fargo raised its price target to $796 from $640, although Meta remains 5% below its year-ago level. Airbnb is up 31% year over year despite higher travel costs, weaker inbound U.S. travel, and growing short-term-rental regulation, while Beam is down 9% year to date after BEAM-302 trial data triggered a nearly 20% three-day selloff despite encouraging efficacy and a potential accelerated FDA approval path.

Analysis

META’s near-term rerating hinges less on consumer app rankings than on whether agentic tools improve ad creation, merchant conversion, or business-messaging monetization. A standalone productivity product could instead increase inference expense without a clear revenue attach, particularly if usage skews toward free consumers. The relevant catalyst is Connect: disclosure of enterprise pricing, API access, WhatsApp integration, or measurable advertiser adoption could support estimates over the next 1-3 months; absent those, the post-event move is vulnerable to a “sell-the-demo” reversal and renewed scrutiny of AI capex returns.

ABNB’s operating leverage remains attractive, but its risk is increasingly geographic rather than cyclical: local inventory restrictions can constrain supply in high-ADR cities, shifting bookings to hotels and benefiting EXPE, BKNG and Marriott franchisees more than they impair broad leisure demand. The market may be underestimating that regulatory enforcement raises customer-acquisition costs and limits take-rate expansion even if gross booking value grows. Over 6-18 months, a more fragmented regulatory regime favors scaled hotel platforms with existing compliance infrastructure; the key near-term falsifier is sustained acceleration in nights booked and take rate despite restricted-market supply.

BEAM is a high-volatility clinical optionality position, not a valuation-driven recovery trade. The critical issue is whether biomarker movement translates into a clinically credible dose-response and an FDA-agreed registrational endpoint; an accelerated pathway is only valuable if confirmatory-trial burden, manufacturing consistency and durability are sufficiently de-risked. Peer read-through from in-vivo editing programs can move the stock before its own updates, but a safety signal or muted follow-up efficacy would likely dominate any sector-beta tailwind.

Contrarian view: Ark’s purchases are weak standalone signals because they do not establish fundamental incremental demand and may attract transient retail flow. The cleaner opportunity is to trade event dispersion: META has a definable product/monetization catalyst, whereas ABNB’s upside requires macro and policy conditions that management cannot fully control, and BEAM requires binary clinical validation.

Key Decisions for Investors

• Maintain a tactical long META only into Connect if implied post-event volatility is below the expected 6-8% move; use a 1-2 month call spread rather than outright stock. Take profits if management emphasizes downloads or engagement without monetization milestones; cut on evidence of incremental AI capex without revenue timing.
• Express the regulatory-supply thesis as long BKNG / short ABNB over 3-6 months, sized modestly. BKNG has broader hotel and international exposure while ABNB has greater sensitivity to constrained urban short-term-rental inventory; exit if ABNB reports nights-booked growth and take-rate expansion materially ahead of BKNG for two consecutive quarters.
• Keep BEAM on an event watchlist rather than add on price weakness alone. Initiate only after updated data show durable, dose-dependent biological effect with no material safety deterioration and management clarifies the FDA registrational path; until then, defined-risk calls around a specified clinical update are preferable to cash equity.
• Do not treat Ark flow as a catalyst. Monitor META options skew and Connect-related estimate revisions, ABNB city-level supply restrictions and cross-border booking trends, and BEAM’s next disclosed efficacy/safety follow-up as the decision variables.